Published online Jan 27, 2025. doi: 10.4240/wjgs.v17.i1.101162
Revised: October 23, 2024
Accepted: November 15, 2024
Published online: January 27, 2025
Processing time: 112 Days and 23.9 Hours
Microwave ablation (MWA) is emerging as a highly effective treatment for colorectal liver metastases (CRLMs). This review explores the advantages of MWA compared to other ablative techniques such as radiofrequency ablation and cryoablation and highlights its clinical efficacy, safety, and technical considerations. MWA offers significant benefits, including higher intratumoral temperatures, larger ablation zones, and reduced susceptibility to the heat-sink effect, which make it particularly suitable for tumors near large blood vessels. This review details the patient selection criteria, procedural approaches, and the use of advanced imaging techniques to improve the precision and effectiveness of MWA. Clinical outcomes indicate that MWA achieves high rates of complete tumor ablation and long-term survival with a favorable safety profile. This review is significant because it provides updated insights into the expanding role of MWA in treating unresectable CRLM and its potential as an alternative to surgical resection for resectable tumors. By summarizing recent studies and clinical trials, this review highlights the comparative effectiveness, safety, and integration with systemic therapies of MWA. In conclusion, MWA is a promising treatment option for CRLM and offers outcomes comparable to or better than those of other ablative techniques. Future research should focus on optimizing technical pa
Core Tip: This review focuses on the application of microwave ablation (MWA) as a treatment for colorectal liver metastasis. MWA offers advantages such as higher intratumoral temperatures, larger ablation zones, and reduced heat-sink effects compared to other techniques such as radiofrequency ablation. This review also discusses the safety and clinical outcomes of MWA and emphasizes its potential as an effective treatment for colorectal liver metastasis. Despite its benefits, this review highlights the need for further research to confirm long-term efficacy and optimize patient selection for better outcomes.